Thursday, June 18, 2020 @ 11:30 am
The Swiss biotechnology industry performed well in 2019, regardless of the macroeconomic and external environment. The industry proved to be resistant to the increased geopolitical, trade policy and tariff challenges: Financing remained sound, revenues increased and mergers and acquisitions continued. At the same time, the industry became even more diverse: gene therapy, artificial intelligence and the production of advanced biologicals developed into complementary strengths.
Read the full German article by Michael Altorfer, CEO Swiss Biotech Association, and Jürg Zürcher, Partner and Biotechnology Leader Germany, Switzerland and Austria, Ernst & Young Zurich: